Loading...
•
Mar 31, 2024
Maravai Q1 2024 Earnings Report
Reported financial results, focusing on product portfolio expansion, market leadership, and scientific innovation.
Key Takeaways
Maravai LifeSciences reported a decrease in revenue to $64.2 million, a net loss of $(22.7) million, and an adjusted EBITDA of $7.8 million for Q1 2024. The company reaffirmed its full-year revenue guidance of $265.0 million to $285.0 million.
Quarterly revenue reached $64.2 million.
Net loss amounted to $(22.7) million.
Adjusted EBITDA was reported at $7.8 million.
Full-year 2024 revenue guidance reaffirmed at $265.0 million to $285.0 million.
Maravai
Maravai
Maravai Revenue by Segment
Revenue by Segment
Nucleic Acid Production Revenue
CapyFin.comBiologics Safety Testing Revenue
CapyFin.com Forward Guidance
Maravai expects full year 2024 revenue to be in the range of $265.0 million to $285.0 million and Adjusted EBITDA margins are expected to be in the range of 23% to 25%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income